Limertinib (ASK120067) is an oral, potent, and selective EGFR tyrosine kinase inhibitor designed to target the T790M resistance mutation. It is a valuable research tool for investigating non-small cell lung cancer (NSCLC) in both in vitro cellular assays and in vivo animal models.